Affimed needs more time with AFM24
Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
ASH 2024 – Astra sets the bar for Merck's Curon buy
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
ASH 2024 – AbbVie fights to rise above the BCMA crowd
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
ASH 2024 – J&J reveals more about Lava's secret sauce
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
BioNTech's pivotal bispecifics plan take shape
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
